Induction Mechanism of PD-L1 (Programmed Cell Death-ligand 1) in Sepsis

被引:0
|
作者
Lee, Sang-Min [1 ,2 ]
机构
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Div Pulm & Crit Care Med, 101,Daehangno, Seoul 110744, South Korea
[2] Seoul Natl Univ, Coll Med, Med Res Ctr, Lung Inst, Seoul, South Korea
关键词
PD-L1; LPS; Sepsis; Macrophage;
D O I
10.4046/trd.2008.65.4.343
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
PD-L1 is expressed in a variety of antigen-presenting cells and provides T cell tolerance via ligation with its receptor PD-1 and B7-1 on T cells. Stimulation with lipopolysaccharide (LPS) can increase the level of PD-L1 expression in B cells and macrophages, which suggests that this molecule plays a role in the immunosuppression observed in severe sepsis. The aim of this study was to identify which of the downstream pathways of TLR4 are involved in the up-regulation of PD-L1 by LPS in macrophages. Flow cytometry was used to examine the expression of PD-L1 in RAW 264.7 macrophages stimulated with LPS. The following chemical inhibitors were used to evaluate the role of each pathway: LY294002 for PI3K/ Akt, SB202190 for p38 MAPK, and U0126 for MEK. LPS induced the expression of PD-L1 in a time-and dose-dependent manner. Transfection of siRNA for TLR4 suppressed the induction of PD-L1. Pretreatment with LY294002 and SB202190 decreased the level of PD-L1 expression but U0126 did not. Overall, the PI3K/ Akt and p38 MAPK pathways are involved in the up-regulation of PD-L1 expression in RAW 264.7 macrophages stimulated with LPS.
引用
收藏
页码:343 / 350
页数:8
相关论文
共 50 条
  • [31] Programmed Death Ligand 1 (PD-L1) Expression in Cervical Cancer
    Lathika, Aryakrishna S.
    Lakshmi, S.
    Ramdas, Preethi T.
    Kumar, Aswin
    Mathews, Susan
    Joseph, John
    Mathew, Aleyamma
    James, Francis V.
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2021, 19 (04)
  • [32] Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome
    Veloza, Luis
    Teixido, Cristina
    Castrejon, Natalia
    Climent, Fina
    Carrio, Ana
    Marginet, Marta
    Soldini, Davide
    Gonzalez-Farre, Blanca
    Ribera-Cortada, Inmaculada
    Lopez-Guillermo, Armando
    Gonzalez-Barca, Eva
    Sierra, Adriana
    Herrera, Mileyka
    Gomez, Candida
    Garcia, Adriana
    Balague, Olga
    Campo, Elias
    Martinez, Antonio
    HISTOPATHOLOGY, 2019, 75 (06) : 799 - 812
  • [33] Programmed death ligand 1 (PD-L1) expression in parathyroid tumors
    Pan, Boju
    Wang, Anqi
    Pang, Junyi
    Zhang, Yuhan
    Cui, Ming
    Sun, Jian
    Liang, Zhiyong
    ENDOCRINE CONNECTIONS, 2019, 8 (07) : 887 - 897
  • [34] Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence
    Lacour, Max
    Hiltbrunner, Stefanie
    Lee, Seok-Yun
    Soltermann, Alex
    Rushing, Elisabeth Jane
    Soldini, Davide
    Weder, Walter
    Curioni-Fontecedro, Alessandra
    CLINICAL LUNG CANCER, 2019, 20 (05) : 391 - 396
  • [35] Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens
    Xu, Huihong
    Bratton, Laura
    Nead, Michael
    Russell, Donna
    Zhou, Zhongren
    CYTOJOURNAL, 2018, 15
  • [36] Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy
    Xipell, M.
    Victoria, I.
    Hoffmann, V.
    Villarreal, J.
    Garcia-Herrera, A.
    Reig, O.
    Rodas, L.
    Blasco, M.
    Poch, E.
    Mellado, B.
    Quintana, L. F.
    ONCOIMMUNOLOGY, 2018, 7 (07):
  • [37] Recent advances in atezolizumab-based programmed death-ligand 1 (PD-L1) blockade therapy for breast cancer
    Ameri, Ali
    Tavakoli-Far, Bahareh
    Rostami, Maryam
    Kiasari, Bahman Abedi
    Sakhaei, Delaram
    Ahmed, Omar Saad
    Forouzani, Fatemeh
    Fazli, Yasaman
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 113
  • [38] Programmed Death-Ligand 1 (PD-L1) Expression in Clinical Practice: Comparison of Temporally or Spatially Separated Test Results
    Deshpande, C.
    Patel, K.
    Litzky, L.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1820 - S1821
  • [39] Expression Analysis of Programmed Death-Ligand (PD-L) 1 in Large Cell Neuroendocrine Carcinoma
    Sakaue, T.
    Nakaoka, H.
    Okazaki, M.
    Shigematsu, H.
    Izutani, H.
    Sano, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S971 - S971
  • [40] Fragment-based screening of programmed death ligand 1 (PD-L1)
    Perry, Evan
    Mills, Jonathan J.
    Zhao, Bin
    Wang, Feng
    Sun, Qi
    Christov, Plamen P.
    Tarr, James C.
    Rietz, Tyson A.
    Olejniczak, Edward T.
    Lee, Taekyu
    Fesik, Stephen
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (06) : 786 - 790